Zubair Ahmed

Dr. Zubair Ahmed

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2026 in ASIDE Case Reports
Verified
Journal Article
Open access
FNFalak Naz
Falak Naz
ZAZubair Ahmed
Zubair Ahmed
ABAbdul Haseeb Bapar
Abdul Haseeb Bapar
FAFnu Asadullah
Fnu Asadullah
MMMayra Z Malik
Mayra Z Malik
MAMuhammad Awais
Muhammad Awais
Bartter syndrome is a rare inherited salt‑wasting tubulopathy characterized by hypokalemia, hypomagnesemia, metabolic alkalosis, and hypercalciuria. Although typically genetic, Bartter‑like phenotypes can occur secondary to nephrotoxic medications such as polymyxins, which induce tubular dysfunction through oxidative and mitochondrial injury. These acquired presentations are underrecognized in critically ill adults receiving salvage antimicrobial therapy. We report a 77‑year‑old woman who developed acute electrolyte wasting consistent with a Bartter‑like phenotype shortly after initiation of polymyxin B for multidrug‑resistant Acinetobacter pneumonia. She developed progressive hypokalemia (2.3–2.9 mmol/L by day 5), hypomagnesemia (1.11 mg/dL by day 6), metabolic alkalosis (bicarbonate 35 mmol/L; chloride 90 mmol/L), and polyuria (4–5.8 L/day). A spot urine sample during hypokalemia (serum potassium 2.6 mmol/L) showed urine potassium 48.9 mmol/L, urine creatinine 31.8 mg/dL, and urine chloride 23 mmol/L, yielding a K/Cr ratio of 154 mmol/g—confirming inappropriate renal potassium wasting. No osmotic diuresis or increased urinary calcium excretion was present. Competing causes, including diuretics, beta‑agonists, gastrointestinal losses, aminoglycosides, amphotericin, and refeeding, were absent. Kidney function remained stable (creatinine 0.76–0.98 mg/dL). Despite aggressive electrolyte replacement, abnormalities persisted until polymyxin B was discontinued on day 14, after which potassium and magnesium normalized within 48 hours and polyuria resolved. Polymyxin-associated nephrotoxicity is well described, but Bartter-like electrolyte-wasting phenotypes are less frequently recognized. The earlier‑than‑typical onset in this patient may reflect advanced age, critical illness, and reduced renal reserve. This case highlights the importance of routine electrolyte surveillance during polymyxin therapy and prompt evaluation for renal wasting when new hypokalemia, hypomagnesemia, or polyuria develops.

5 October 2026 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
ZAZubair Ahmed
Zubair Ahmed
FNFalak Naz
Falak Naz
KCKanchan Chaudhary
Kanchan Chaudhary
VDVishan Das
Vishan Das
OSOmran Shrebaty
Omran Shrebaty
CSCharles Sineri
Charles Sineri
Introduction: Aortic stenosis (AS) and atrial fibrillation (AF) frequently coexist in older adults and are associated with increased cardiovascular risk. National mortality trends involving both conditions remain incompletely characterized. Methods: We performed a nationwide ecological time-trend analysis using the CDC WONDER Multiple Cause of Death database from 1999 to 2024. Adults aged ≥ 55 years with both AS (ICD-10 I35.0) and AF (ICD-10 I48) listed on the death certificate were included. Age-adjusted mortality rates (AAMRs) per 100,000 populations were analyzed overall and by sex, race/ethnicity, census region, urbanization, and place of death. Temporal trends were assessed using Joinpoint regression. Results: A total of 94,542 deaths involving AS and AF were identified. Overall AAMR increased from 2.4 (95% confidence interval [CI], 2.3–2.6) in 1999 to 7.4 (95% CI, 7.2–7.6) in 2024, with a significant overall increase (average annual percent change [AAPC], 5.08%; p < 0.001). Mortality remained higher among males than females (2024 AAMR: 9.2 vs. 6.1 per 100,000). NH White individuals had the highest mortality rates, while all racial and ethnic groups demonstrated significant increases over time. Mortality was highest in the Western United States and in non-metropolitan areas. Most deaths occurred in inpatient facilities (33.8%), followed by home (29.0%) and nursing homes or long-term care facilities (22.6%). Conclusion: Mortality involving coexisting AS and AF increased more than threefold among U.S. adults aged ≥ 55 years between 1999 and 2024. Persistent demographic and geographic disparities highlight the need for earlier diagnosis and improved access to guideline-directed care. Clinical trial number: Not applicable.

29 December 2025 in ASIDE Case Reports
Verified
Journal Article
Open access
PDF file
FNFalak Naz
Falak Naz
FAFarhan Ali
Farhan Ali
ZAZubair Ahmed
Zubair Ahmed
BABarkha
Barkha
SAShaista Ali
Shaista Ali
ASAsadullah
Asadullah
Brucellosis is a zoonotic infection caused by Brucella species, most commonly B. melitensis and B. abortus. While systemic symptoms such as fever and arthralgia are well recognized, cutaneous manifestations are rare, occurring in only 0.4–17% of cases. A 30-year-old male shepherd with a 10-week history of high-grade intermittent fever and severe back pain, and 2 weeks later, he developed rash. Dermatologic examination revealed multiple hyperpigmented macules and scattered erythematous papules on the back. Laboratory findings showed mild anemia (Hb 10.2 g/dL) with otherwise normal hematologic and biochemical parameters. Serology demonstrated elevated titers for Brucella abortus(1:200) and Brucella melitensis(1:80), and two sets of aerobic blood cultures became positive after 5 days using the identified Brucella spp. (species not further resolved). The patient was treated with doxycycline (100 mg twice daily for 6 weeks) and streptomycin (1 g intramuscularly daily for 2 weeks). A follow-up after 3 months, the patient remained asymptomatic with no relapse; repeat serology showed declining titers. In occupationally exposed individuals with prolonged fever, early consideration of brucellosis and proper serologic/culture confirmation can prevent diagnostic delays, even when presentations include uncommon features such as prominent cutaneous involvement.

10 July 2026 in ASIDE Endocrinology
Verified
Journal Article
Open access
PDF file
ZAZubair Ahmed
Zubair Ahmed
FNFalak Naz
Falak Naz
KOKayode Ogunniyi
Kayode Ogunniyi
KCKanchan Chaudhary
Kanchan Chaudhary
SAShaista Ali
Shaista Ali
LALaksh Kumar Ahuja
Laksh Kumar Ahuja
BackgroundHeart failure frequently coexists with cardiometabolic conditions commonly associated with metabolic syndrome. Characterizing long-term mortality patterns involving these co-reported conditions may help identify populations with a disproportionate burden. MethodsWe performed a national serial cross‑sectional analysis using the CDC WONDER Multiple Cause of Death database to examine mortality among U.S. adults aged ≥25 years from 1999 to 2023. Eligible deaths included those with at least one heart failure ICD‑10 code and at least one metabolic syndrome–related ICD–10 code recorded anywhere on the death record. Age‑adjusted mortality rates (AAMRs) per 100,000 population were calculated using the 2000 U.S. standard population. Temporal trends were assessed using Joinpoint regression and stratified by sex, race/ethnicity, U.S. Census region, urbanization (1999–2020), and state. ResultsA total of 1,562,715 deaths co‑reporting heart failure and metabolic syndrome–related conditions were identified. The overall AAMR increased from 24.7 in 1999 to 38.3 in 2023. After declining from 2005 to 2012, mortality increased beginning in the mid-2010s, with a pronounced acceleration during 2018–2021 and a modest decline thereafter. AAMRs were higher among men, non-Hispanic Black and American Indian or Alaska Native populations, residents of the Midwest (with comparatively elevated rates also observed in the West and South), and individuals in nonmetropolitan areas. ConclusionsMortality involving deaths co‑reporting heart failure and metabolic syndrome–related conditions increased substantially after 2012, with marked disparities by sex, race/ethnicity, geography, and urbanization, underscoring the need for equity‑focused cardiometabolic prevention strategies.

21 February 2026 in ASIDE Case Reports
Verified
Journal Article
Open access
ZAZubair Ahmed
Zubair Ahmed
FNFalak Naz
Falak Naz
ASAsadullah
Asadullah
PEPaghunda Ehsan
Paghunda Ehsan
SAShaista Ali
Shaista Ali
MRMuhammad Rizwan
Muhammad Rizwan
Mollaret meningitis is a rare, recurrent form of aseptic lymphocytic meningitis, most commonly caused by herpes simplex virus type 2 infection. The clinical presentation includes sudden, recurring attacks of headache, meningismus, and lymphocytic cerebrospinal fluid pleocytosis that resolve spontaneously. We report a case of a 45‑year‑old woman with known HSV‑2 infection and two prior episodes of presumed viral meningitis who presented with progressive bitemporal headache, photophobia, nausea, vomiting, and fever. Neurologic examination was intact, and brain CT and MRI were unremarkable. Lumbar puncture revealed an opening pressure of 42 cm H₂O. CSF analysis showed WBC 441/µL (92% lymphocytes), protein 77.2 mg/dL, glucose 72 mg/dL (serum 116 mg/dL), and negative Gram stain and culture. A multiplex meningitis PCR panel was negative; however, targeted testing detected HSV‑2 DNA in CSF, confirming the diagnosis. Empiric dexamethasone (8mg IV q6hr), ceftriaxone (2G IV q12hr), vancomycin (1G IV q12hr), and acyclovir (10mg/kg/dose IV q8hr) were initiated, and antibacterial therapy was discontinued once HSV‑2 PCR positivity was established. The patient improved with supportive care. Her headache partially improved after CSF drainage and progressively resolved over the course of the hospitalization. She remained neurologically stable without visual changes and was discharged with outpatient neurology and ophthalmology follow‑up to monitor for recurrent symptoms or signs of intracranial hypertension. This case highlights HSV‑2–associated Mollaret meningitis presenting with markedly elevated CSF opening pressure, underscoring the importance of targeted CSF PCR during symptomatic episodes and the need for structured follow‑up, given the risk of recurrence and the potential for intracranial hypertension.

19 May 2026 in ASIDE Case Reports
Verified
Journal Article
Open access
PDF file
SSSalar Shahzad
Salar Shahzad
ZAZubair Ahmed
Zubair Ahmed
FNFalak Naz
Falak Naz
IAIkenna De-Jason Anusionwu
Ikenna De-Jason Anusionwu
TZTehseen Zahra
Tehseen Zahra
JNJay Nfonoyim
Jay Nfonoyim
Mechanical thrombectomy is an established treatment for acute ischemic stroke due to large‑vessel occlusion, and transfemoral access is generally safe. However, access‑site complications, though uncommon, can be severe. We report a fatal femoral access‑site pseudoaneurysm occurring after multimodal endovascular stroke reperfusion therapy. A 69‑year‑old woman presented with acute left hemiparesis and was found to have a right M2 occlusion. She received intravenous tenecteplase followed by emergent mechanical thrombectomy via right femoral access, with complete reperfusion achieved. The procedure also required carotid angioplasty, closure‑device deployment, and periprocedural eptifibatide. Within hours, she developed an enlarging groin hematoma and early livedo reticularis of the thigh. Duplex ultrasound revealed a large femoral pseudoaneurysm, later localized angiographically to the profunda femoris–superficial femoral artery bifurcation. Despite urgent endovascular exclusion with a covered stent graft, she arrived in hemorrhagic shock and progressed to profound metabolic acidosis, multiorgan failure, and death from hypovolemic shock. This case highlights how the combination of complex aortoiliac anatomy, large‑bore transfemoral access, closure‑device use, and potent antithrombotic exposure can predispose to rapid pseudoaneurysm expansion and severe hemorrhage. The early appearance of livedo reticularis represents a potentially important cutaneous warning sign of evolving vascular injury. Although limited to a single case, these observations underscore the need for careful access planning in anatomically challenging patients and prompt evaluation of early groin changes or unexplained clinical decline following endovascular stroke therapy.